On Jan. 28, 2020, AbCellera confirmed that it had mobilized its pandemic response platform against the ongoing outbreak of a novel coronavirus (2019-nCoV) originating in Wuhan, China. Since 2018, under the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program, AbCellera lead a team of partners to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

AbCellera’s rapid, high-throughput therapeutic antibody discovery technology was used to discover coronavirus-neutralizing antibodies that could ultimately be deployed to stop transmission of the 2019-nCoV outbreak.